Skip 
Navigation Link
Medical Disorders
Resources
Basic InformationLookupsLatest News
Family History Questionnaire Ups Genetic Counseling for CRCBlood Test Can Detect GLUT1 Deficiency SyndromeWallpaper May Breed Toxins: StudyFish Eaters Report Less Rheumatoid Arthritis PainGuided Exercise May Help Chronic Fatigue Patients: Study2006 to 2013 Saw Increase in ER Use for Herpes ZosterNearly 60 Percent With Conjunctivitis Fill Antibiotic RxTissue Testing Can Spot Zika at Birth: CDCGuidelines Address Peri-Op Care in Rheumatic DiseaseZika-Bearing Mosquitoes More Widespread in U.S. Than ExpectedMarital Status Among Factors Tied to Gout Rx AdherenceMany Chronic Illnesses Linked to Suicide RiskVaccine Curbs High Cholesterol in MiceStudy Hints at Link Between Some Statins, Parkinson's RiskHydrotherapy Plus Conventional Drugs Beneficial in RAChronic Lyme Disease Treatments Tied to Serious Adverse EffectsOlder Age Needn't Be a Barrier to Herniated Disc SurgeryNon-Opioid Drug More Effective for Migraines: StudyHealth Tip: Managing Arthritis FatigueCertain Criteria May Be Better Than Others in RA Assessment20 Percent of Hospital Patients Have Side Effects From Abx RxRecreational Activity-Linked Facial Fractures Up in SeniorsUnusual Measles Outbreak Described in Ontario in Early 2015Seniors Get Good Results From Herniated Disc Surgery'Good' Donor Bacteria Can Last Long Term in Stool Transplant PatientsNovel Retinal Lesion Seen in Some Ebola SurvivorsHealth Tip: Recognizing Summer Allergy SymptomsAre You at Risk for Metabolic Syndrome?Antiplatelet Bleeding Risk Higher Than Expected for Older PatientsVideo Call May Be as Good as Doctor Visit for HeadacheCould Prefab Blood Vessels Revolutionize Root Canals?A Sufferer's Guide to Easin' Sneezin' SeasonHospitals Get Good News About Fighting Staph InfectionsCases of Legionnaires' Disease Reported in NYC, Las VegasOlive Oil, Ibuprofen May Have Synergistic EffectsObesity Prevalence Has Doubled in More Than 70 CountriesSeveral New Medications in the Pipeline to Prevent MigraineReview: Depression Screening As Inpatient Important, FeasibleVitamin B6 Linked to Increased Risk of Hip Fracture2 Billion Worldwide Are Obese or OverweightPatient's Education Level May Be Key to Heart RiskMeds Rooted in Ancient China May Help Heart: ReviewBats Harbor Viruses That Could Cause Outbreaks in HumansExperimental Zika Vaccine Protects Mice Against Virus: StudyGlobal Climate Change Could Cause Rise in Airway IrritationEqual Wound Complications for Staples, Suture in Obese WomenDepression Can Slow Hospital Patients' Recovery: StudyEven Your Bones Can Get Fat, Mouse Study SuggestsNew Drugs Show Promise as First to Prevent Migraine1 in 7 Americans Has Kidney Disease: CDC
Questions and AnswersLinksBook Reviews
Related Topics

Three-Drug Combo Pill Nearly 100 Percent Effective in Curing Hep C


HealthDay News
Updated: Jun 1st 2017

new article illustration

THURSDAY, June 1, 2017 (HealthDay News) -- A pill containing the antiviral drugs sofosbuvir, velpatasvir, and voxilaprevir is nearly 100 percent effective in curing hepatitis C in patients whose disease returned after treatment with direct-acting antiviral agents, according to research published in the June 1 issue of the New England Journal of Medicine.

In two phase 3 trials, Marc Bourlière, M.D., from the Hospital Saint Joseph in Marseilles, France, and colleagues treated patients with the combination pill or a placebo or other antiviral drugs. In the first trial, 300 patients were randomly assigned to either the combination pill or a placebo (150 patients in each group). These patients all had hepatitis C genotype 1. In addition, 114 patients with other genotypes of hepatitis C were given the combination pill. Patients took the pill daily for 12 weeks. Among patients taking the combination pill, 96 percent responded to treatment. None on the placebo showed a response, the researchers found.

The second trial included 314 patients with hepatitis C genotypes 1, 2 or 3. All had failed other treatments, but hadn't been given a NS5A inhibitor, such as velpatasvir or daclatasvir. This group received either the combination pill (163 patients) or sofosbuvir-velpatasvir (151 patients). In addition, 19 patients with genotype 4 hepatitis C were given the combination pill. In this trial, 98 percent of the patients taking the combination pill responded to 12 weeks of treatment. And 90 percent of those who received sofosbuvir-velpatasvir responded to treatment, the investigators found.

The most common side effects were headache, fatigue, diarrhea, and nausea. Only 1 percent or fewer patients stopped treatment because of the side effects. This new pill is being developed as a rescue treatment for patients who have failed other therapy, Bourlière told HealthDay. When it was used as an initial treatment in another study, the combination pill fared no better than the usual treatment, he said.

The study was funded by Gilead Sciences, the manufacturer of the combination pill.

Abstract/Full Text (subscription or payment may be required)